ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations
ICR, a leading global strategic communications and advisory firm, today announced it has acquired Consilium Strategic Communications, a leading international strategic healthcare communications and investor relations firm focused on Europe and headquartered in London. The transaction, which follows almost a decade of joint venture collaboration, will combine Consilium with ICR’s US-based healthcare practice, ICR Westwicke, forming a global healthcare strategic and financial communications powerhouse with nearly 200 clients and more than 100 team members across three continents.
Current clients of Consilium will immediately benefit from the full breadth of ICR’s services including: investor relations; capital markets and IPO advisory; investor access; ESG advisory; corporate communications and media relations; crisis and special situations; marketing PR; social media; and branding & design. Consilium will operate under the “ICR Consilium” brand and integrate its teams and activities with ICR’s existing healthcare practice.
Consilium was formed in 2013 by Mary-Jane Elliott, Founder and Managing Partner, along with Amber Fennell, Senior Partner and Co-founder. Over the past 10 years the firm has grown to become the market leader in healthcare strategic communications and IR in Europe. Mary-Jane Elliott will continue to lead the firm from its headquarters in London and both she and Amber Fennell will join the ICR healthcare leadership team, which includes Mark Klausner and Bob East (for Investor Relations), and Terri Clevenger and Michael O’Brien (for Public Relations). The transaction establishes ICR’s first official on-the-ground presence in Europe, broadening its global footprint to now include North America, Asia Pacific and UK/Europe.
Tom Ryan, Founder & CEO of ICR, said: “Consilium has long been recognized as the preeminent healthcare communications and advisory firm across Europe and our years of collaboration have allowed us to learn first-hand what makes them so unique. MJ, Amber and their team have built an incredible business, with a hard-earned reputation for deep sector expertise, highly strategic counsel and outstanding client service. Their business and culture could not align more perfectly with ICR’s and we are thrilled to advance our partnership as a single, unified team.
“We were fortunate to add the Westwicke team to ICR in 2019 and have enjoyed tremendous success since then, growing our healthcare practice nearly three-fold. Combining the Consilium and ICR Westwicke teams allows us to offer truly comprehensive global support to healthcare companies while also extending ICR’s presence into Europe,” Mr. Ryan continued.
Mary-Jane Elliott, Managing Partner at ICR Consilium, said: "Over the past 10 years we have had the great pleasure to build Consilium into Europe's leading independent strategic communications agency for the healthcare sector with the sole purpose of serving our clients globally. I am extremely proud of what we have achieved as a team and thank our clients, colleagues past and present, and fellow advisors for their ongoing trust and support.
"I am excited by our next phase of growth as part of ICR, who are backed by two leading global private equity firms – CDPQ and Investcorp, and what opportunities this offers, particularly in the US, to our clients and colleagues, including offering a broader range of capabilities. We have been joint-venture partners for almost a decade and have a complementary fit in international healthcare PR and IR advisory work. Over the years of working with ICR we have shared many clients and delivered fantastic and seamless benefits, as well as formed strong relationships with the ICR team across the US. Now is the right time to deepen that relationship, which coincides with hopefully the continued re-opening of the capital markets, and we look forward to what we can accomplish together,” Mary-Jane Elliott added.
This transaction creates one of the largest global specialist healthcare communications practices and significantly enhances ICR’s capabilities in Europe, by increasing its practice size in both revenue and headcount and broadening its service offerings. The ICR and Consilium combination will immediately provide existing and new ICR Consilium clients with access to integrated support across ICR’s entire platform of services and the combination creates exciting new growth opportunities for all team members.
Together, ICR and Consilium bring unmatched depth of expertise in healthcare advisory services across IR and strategic communications and the capabilities to support healthcare companies globally across all subsectors including biopharma, medical technology, diagnostics, healthcare services and information technology, and through all stages of growth from early-stage development, to public offerings, to mature public companies. The firm’s full range of critical strategic communication and investor relations services enable the combined team to support healthcare businesses and leaders with strategic expertise for gaining investor support, building and managing reputation, executing and communicating capital raising and other transactions, responding to crises, introducing new products, communicating regulatory developments and more.
Consilium's team of more than 45 PR and IR professionals, including former journalists, sell-side analysts, industry communications experts, and financial PR practitioners combines with ICR Westwicke’s more than 70 team members with similar professional backgrounds in healthcare. Consilium adds to ICR’s existing client base and bolsters the firm’s expertise in strategic healthcare communications and investor relations, with deep industry knowledge and an unrivalled network across the US, UK, continental Europe and Asia.
Amber Fennell, Senior Partner, ICR Consilium, added: “The combination of Consilium with ICR creates an unrivalled transatlantic strategic communications practice providing support across all aspects of healthcare corporate communications and financial transactions. ICR has an excellent brand and reputation and is one of the fastest growing communications agencies in the US. Working together we will be able to provide our combined healthcare clients with even more seamless and integrated access to a breadth of PR and IR advisory services, in London, across Europe and in the US.”
Notes to editors
About ICR
Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the ICR Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Diego, San Jose and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR and LinkedIn.
About ICR Consilium
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information, please see www.consilium-comms.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912400327/en/
Contact information
For more information:
ICR
Matt Lindberg
Tel: +1(203) 644-7028
Matthew.Linberg@icrinc.com
ICR Consilium
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
info@consilium-comms.com
www.consilium-comms.com
Follow us: @consiliumhc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
